[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade",
    "summary": "In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=d6418dc048d57c33c23f9a0e0638ba8f1a4b062ec679d8c828164c96799d3451",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750716002,
      "headline": "Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade",
      "id": 135487195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=d6418dc048d57c33c23f9a0e0638ba8f1a4b062ec679d8c828164c96799d3451"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Rally on Hopes of De-Escalation of Hostilities in the Middle East",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.96%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.06%. September E-mini S&P futures (ESU25 ) are up +0.96%, and September E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=c6cf77b578dbb2917d91a858f53c6d55ba2c57b2ee8f4319cff22294e1dfd0c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750712040,
      "headline": "Stocks Rally on Hopes of De-Escalation of Hostilities in the Middle East",
      "id": 135485874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.96%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.06%. September E-mini S&P futures (ESU25 ) are up +0.96%, and September E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=c6cf77b578dbb2917d91a858f53c6d55ba2c57b2ee8f4319cff22294e1dfd0c8"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Shares Fall on Weight-Loss Drug Tummy Troubles",
    "summary": "At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.",
    "url": "https://finnhub.io/api/news?id=9a1532c9b7acdd1fddda703e9cdca95baa0515f6dc3cd918b96c24a031a5f8c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750709700,
      "headline": "Amgen Shares Fall on Weight-Loss Drug Tummy Troubles",
      "id": 135486657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.",
      "url": "https://finnhub.io/api/news?id=9a1532c9b7acdd1fddda703e9cdca95baa0515f6dc3cd918b96c24a031a5f8c1"
    }
  },
  {
    "ts": null,
    "headline": "American Diabetes Association 85th Scientific Session",
    "summary": "American Diabetes Association 85th Scientific Session",
    "url": "https://finnhub.io/api/news?id=df35b2f69b0d8fcf0df0a8a2e8fcb8d252f61cf0a3d541df5f00220d9aeff838",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750708319,
      "headline": "American Diabetes Association 85th Scientific Session",
      "id": 135485767,
      "image": "",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=df35b2f69b0d8fcf0df0a8a2e8fcb8d252f61cf0a3d541df5f00220d9aeff838"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Amgen Inc. - Special Call",
    "summary": "Presentation Operator MessageOperator My name is Julianne, and I will be your conference facilitator today for the Amgen Conference Call from the American Diabetes Association 85th Scientific",
    "url": "https://finnhub.io/api/news?id=4d60f43823423c8f5d0f4924869507225341c012aa0be5511143a3f0783e369c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750708217,
      "headline": "Transcript : Amgen Inc. - Special Call",
      "id": 135485782,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Presentation Operator MessageOperator My name is Julianne, and I will be your conference facilitator today for the Amgen Conference Call from the American Diabetes Association 85th Scientific",
      "url": "https://finnhub.io/api/news?id=4d60f43823423c8f5d0f4924869507225341c012aa0be5511143a3f0783e369c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen stock slips, weight-loss drug moves to phase 3 trial",
    "summary": "Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with participants getting to the highest dose level through a three-step dose escalation. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=5bd79cec97a7a4ffcb23f3c88836b93d20ed3b60ef77630e2227464247cc128f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750708198,
      "headline": "Amgen stock slips, weight-loss drug moves to phase 3 trial",
      "id": 135487198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with participants getting to the highest dose level through a three-step dose escalation. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=5bd79cec97a7a4ffcb23f3c88836b93d20ed3b60ef77630e2227464247cc128f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
    "summary": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
    "url": "https://finnhub.io/api/news?id=f25d8a2b9e288fb49d127c8391a9611c43c3daf14d4ba9b131e6a25874402f6d",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750706210,
      "headline": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
      "id": 135498556,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent",
      "url": "https://finnhub.io/api/news?id=f25d8a2b9e288fb49d127c8391a9611c43c3daf14d4ba9b131e6a25874402f6d"
    }
  },
  {
    "ts": null,
    "headline": "RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS",
    "summary": "Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to these data, complete results from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented as part of an expert-led Symposium at the 85th American Diabetes As",
    "url": "https://finnhub.io/api/news?id=e4649daf45c04d6b351eaecb9d21aa12576d755ecc906f3139a5bfdc86a7bb63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750703460,
      "headline": "RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS",
      "id": 135487199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to these data, complete results from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented as part of an expert-led Symposium at the 85th American Diabetes As",
      "url": "https://finnhub.io/api/news?id=e4649daf45c04d6b351eaecb9d21aa12576d755ecc906f3139a5bfdc86a7bb63"
    }
  },
  {
    "ts": null,
    "headline": "Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment",
    "summary": "Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.",
    "url": "https://finnhub.io/api/news?id=731535931fe6e0fad4df2a157e1e3b4e0556bad018d45fa3cb2bdac0b20606ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750703415,
      "headline": "Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment",
      "id": 135487200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=731535931fe6e0fad4df2a157e1e3b4e0556bad018d45fa3cb2bdac0b20606ee"
    }
  },
  {
    "ts": null,
    "headline": "Amgen experimental weight-loss drug needs lower dose to limit side effects",
    "summary": "Amgen's long-acting experimentalobesity drug MariTide needs to be given at a low starting doseto limit side effects like vomiting, according to mid-stagetrial results presented at a medical meeting...",
    "url": "https://finnhub.io/api/news?id=6ddcc139c63eea9bf6d38b1078f2d731abf61a66abb5b4bf2d2c7b1a959cfcfd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750697950,
      "headline": "Amgen experimental weight-loss drug needs lower dose to limit side effects",
      "id": 135485158,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen's long-acting experimentalobesity drug MariTide needs to be given at a low starting doseto limit side effects like vomiting, according to mid-stagetrial results presented at a medical meeting...",
      "url": "https://finnhub.io/api/news?id=6ddcc139c63eea9bf6d38b1078f2d731abf61a66abb5b4bf2d2c7b1a959cfcfd"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update",
    "summary": "By Katherine Hamilton Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea. In a phase 2 trial, the drug demonstrated 20%...",
    "url": "https://finnhub.io/api/news?id=b001a48e318360a9fd8e7605f30194dc3bc875cf7fcec89f82b4fd6b35982dae",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750692309,
      "headline": "Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update",
      "id": 135484764,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "By Katherine Hamilton Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea. In a phase 2 trial, the drug demonstrated 20%...",
      "url": "https://finnhub.io/api/news?id=b001a48e318360a9fd8e7605f30194dc3bc875cf7fcec89f82b4fd6b35982dae"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial",
    "summary": "Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial",
    "url": "https://finnhub.io/api/news?id=7259630c48debfdcc0b22173f8d76048e3e1c198e994f2701b76cdfff215fd73",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750691340,
      "headline": "Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial",
      "id": 135500673,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial",
      "url": "https://finnhub.io/api/news?id=7259630c48debfdcc0b22173f8d76048e3e1c198e994f2701b76cdfff215fd73"
    }
  },
  {
    "ts": null,
    "headline": "Low start dose of Amgen experimental weight-loss drug limits side effects",
    "summary": "People started on a low dose ofAmgen's long-acting experimental obesity drug MariTide lost asmuch weight as those given high doses but with milder sideeffects, according to full results of a...",
    "url": "https://finnhub.io/api/news?id=ed68d03d740eebbaf22a4e85d0de381f69d4d135d1a820d0d1aa718e846d7e94",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750689072,
      "headline": "Low start dose of Amgen experimental weight-loss drug limits side effects",
      "id": 135484565,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "People started on a low dose ofAmgen's long-acting experimental obesity drug MariTide lost asmuch weight as those given high doses but with milder sideeffects, according to full results of a...",
      "url": "https://finnhub.io/api/news?id=ed68d03d740eebbaf22a4e85d0de381f69d4d135d1a820d0d1aa718e846d7e94"
    }
  },
  {
    "ts": null,
    "headline": "American Express, Amgen share losses contribute to Dow's 100-point drop",
    "summary": "American Express, Amgen share losses contribute to Dow's 100-point drop",
    "url": "https://finnhub.io/api/news?id=23c4a1c5b1a620244bf1ab3756d2d86716cab65f31b9e1a87f9fae948ee3ad25",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750681920,
      "headline": "American Express, Amgen share losses contribute to Dow's 100-point drop",
      "id": 135499241,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "American Express, Amgen share losses contribute to Dow's 100-point drop",
      "url": "https://finnhub.io/api/news?id=23c4a1c5b1a620244bf1ab3756d2d86716cab65f31b9e1a87f9fae948ee3ad25"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One",
    "summary": "Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.",
    "url": "https://finnhub.io/api/news?id=4e760033ba4821df79b081935dac0af426335dcaf89076ab9b635b322cd8a901",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750670283,
      "headline": "Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One",
      "id": 135475110,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962515/image_1386962515.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.",
      "url": "https://finnhub.io/api/news?id=4e760033ba4821df79b081935dac0af426335dcaf89076ab9b635b322cd8a901"
    }
  }
]